AstraZeneca’s COVID vaccine is more likely to cause thrombosis, the study says

Since the start of COVID-19 vaccination campaigns around the world, there have been a few strange cases of thrombosis after applying the first doses, and a recent study revealed that the biologist from the AstraZeneca company is one of those who have given the most cases so far.

Research carried out by British medical journal notes that COVID adenovirus vaccines were the ones that caused the biggest cases of thrombosis and the main companies that run these biologists are AstraZeneca and Johnson & Johnson.

COVID RNA vaccines (like Pfizer’s), meanwhile, have had a lower, but existing, presence of thrombosis cases, so there is less concern.

Research indicates that “there is a causal relationship between these vaccines and thrombosis with thrombocytopenia syndrome, which led to an update of the product information for the AstraZeneca vaccine to include thrombosis with thrombocytopenia syndrome as a very rare side effect. ”

The research goal was only to quantify the risk of thrombosis, as it argues that the response to vaccines was the reason COVID-19 lowered its lethality.

“After excluding many analyzes due to identified confounders or limited statistical power, we observed a 30 percent increase in risk thrombocytopenia after the first dose of ChAdOx1-S (AstraZeneca) versus the first dose of BNT162b2 (Pfizer), “concluded the study.

He also pointed out that the risk is greater in the first dose of the COVID vaccine, and that in the second dose it does not increase the possibility of thrombosis.